Biotech remains compelling even after major comeback. Here’s what investors say

Biotech is back, baby! A wave of life science deals is pumping cash into the sector. - The Boston Globe

There has already been $85 billion worth of large life science acquisitions this year.

Biotech remains compelling even after major comeback. Here’s what investors say

The healthcare subsector has quietly become one of the most attractive opportunities this year.

Biotech Is Up 80% in 12 Months — and Investors Say the Rally Has More Room to Run

Biotech has staged one of the most dramatic comebacks in the market this year, and veteran fund managers say the rally is far from over. The State Street SPDR S&P Biotech ETF (XBI) has surged nearly 80% over the past 12 months, while the iShares Biotechnology ETF (IBB) is up more than 40%. For comparison, the S&P 500 is up about 19% over the same period. The sector is being driven by a powerful combination: a wave of expiring pharmaceutical pate…

The biotech recovery gathers speed in Q2

It’s always darkest before the biotech dawn, and at no time was that more true than last summer, as biotech was experiencing a crisis of confidence. We tracked an industry-wide downturn in expectations during the ...